{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:28:02Z","timestamp":1707524882690},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,24]]},"DOI":"10.7759\/cureus.34143","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T13:57:26Z","timestamp":1674568646000},"source":"Crossref","is-referenced-by-count":0,"title":["Vitiligo in a Patient With Kabuki Syndrome: Case Study and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Karli","family":"Gage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda S","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"McBride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-015-8707-4","article-title":"Epigenetic control of the immune system: a lesson from Kabuki syndrome","volume":"64","author":"Stagi S","year":"2016","unstructured":"Stagi S, Gulino AV, Lapi E, Rigante D. Epigenetic control of the immune system: a lesson from Kabuki syndrome. Immunol Res. 2016, 64:345-59. 10.1007\/s12026-015-8707-4","journal-title":"Immunol Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0623-x","article-title":"Immunopathological manifestations in Kabuki syndrome: a registry study of 177 individuals","volume":"22","author":"Margot H","year":"2020","unstructured":"Margot H, Boursier G, Duflos C, et al.. Immunopathological manifestations in Kabuki syndrome: a registry study of 177 individuals. Genet Med. 2020, 22:181-8. 10.1038\/s41436-019-0623-x","journal-title":"Genet Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2006.11.004","article-title":"Kabuki syndrome with trichrome vitiligo, ectodermal defect and hypogammaglobulinemia A and G","volume":"29","author":"Zannolli R","year":"2007","unstructured":"Zannolli R, Buoni S, Macucci F, et al.. Kabuki syndrome with trichrome vitiligo, ectodermal defect and hypogammaglobulinemia A and G. Brain Dev. 2007, 29:373-6. 10.1016\/j.braindev.2006.11.004","journal-title":"Brain Dev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.30332","article-title":"Autoimmune disorders in Kabuki syndrome","volume":"132A","author":"Ming JE","year":"2005","unstructured":"Ming JE, Russell KL, McDonald-McGinn DM, Zackai EH. Autoimmune disorders in Kabuki syndrome. Am J Med Genet A. 2005, 132A:260-2. 10.1002\/ajmg.a.30332","journal-title":"Am J Med Genet A"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2018-105625","article-title":"Kabuki syndrome: international consensus diagnostic criteria","volume":"56","author":"Adam MP","year":"2019","unstructured":"Adam MP, Banka S, Bjornsson HT, et al.. Kabuki syndrome: international consensus diagnostic criteria. J Med Genet. 2019, 56:89-95. 10.1136\/jmedgenet-2018-105625","journal-title":"J Med Genet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2018.09.005","article-title":"Systemic lupus erythematosus: a new autoimmune disorder in Kabuki syndrome","volume":"62","author":"Arsov T","year":"2019","unstructured":"Arsov T, Sestan M, Cekada N, et al.. Systemic lupus erythematosus: a new autoimmune disorder in Kabuki syndrome. Eur J Med Genet. 2019, 62:103538. 10.1016\/j.ejmg.2018.09.005","journal-title":"Eur J Med Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04108-w","article-title":"Clinical heterogeneity of Kabuki syndrome in a cohort of Italian patients and review of the literature","volume":"181","author":"Di Candia F","year":"2022","unstructured":"Di Candia F, Fontana P, Paglia P, et al.. Clinical heterogeneity of Kabuki syndrome in a cohort of Italian patients and review of the literature. Eur J Pediatr. 2022, 181:171-87. 10.1007\/s00431-021-04108-w","journal-title":"Eur J Pediatr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.30144","article-title":"Atypical findings in Kabuki syndrome: report of 8 patients in a series of 20 and review of the literature","volume":"129A","author":"Genevi\u00e8ve D","year":"2004","unstructured":"Genevi\u00e8ve D, Amiel J, Viot G, et al.. Atypical findings in Kabuki syndrome: report of 8 patients in a series of 20 and review of the literature. Am J Med Genet A. 2004, 129A:64-8. 10.1002\/ajmg.a.30144","journal-title":"Am J Med Genet A"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00019605-200110000-00004","article-title":"Clinical phenotypes of nine cases of Kabuki syndrome from New Zealand","volume":"10","author":"McGaughran J","year":"2001","unstructured":"McGaughran J, Aftimos S, Jefferies C, Winship I. Clinical phenotypes of nine cases of Kabuki syndrome from New Zealand. Clin Dysmorphol. 2001, 10:257-62. 10.1097\/00019605-200110000-00004","journal-title":"Clin Dysmorphol"},{"key":"ref10","article-title":"Kabuki make-up (Niikawa-Kuroki) syndrome in a girl presenting with vitiligo vulgaris, cleft palate, somatic and psychomotor retardation and facial dysmorphism","volume":"4","author":"Schrander-Stumpel C","year":"1993","unstructured":"Schrander-Stumpel C, Theunissen P, Hulsmans R, Fryns JP. Kabuki make-up (Niikawa-Kuroki) syndrome in a girl presenting with vitiligo vulgaris, cleft palate, somatic and psychomotor retardation and facial dysmorphism. Genet Couns. 1993, 4:71-2.","journal-title":"Genet Couns"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19981204)80:4<362::AID-AJMG11>3.0.CO;2-W","article-title":"Severe congenital anomalies requiring transplantation in children with Kabuki syndrome","volume":"80","author":"Ewart-Toland A","year":"1998","unstructured":"Ewart-Toland A, Enns GM, Cox VA, Mohan GC, Rosenthal P, Golabi M. Severe congenital anomalies requiring transplantation in children with Kabuki syndrome. Am J Med Genet. 1998, 80:362-7. 10.1002\/(SICI)1096-8628(19981204)80:4&lt;362::AID-AJMG11&gt;3.0.CO;2-W","journal-title":"Am J Med Genet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.2686","article-title":"Coexistence of Kabuki syndrome and autoimmune thyroiditis","volume":"8","author":"G\u00fcrb\u00fcz F","year":"2016","unstructured":"G\u00fcrb\u00fcz F, \u00d6zalp Y\u00fcre\u011fir \u00d6, Ceylaner S, Topalo\u011flu AK, Y\u00fcksel B. Coexistence of Kabuki syndrome and autoimmune thyroiditis. J Clin Res Pediatr Endocrinol. 2016, 8:105-6. 10.4274\/jcrpe.2686","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000228114.06488.ef","article-title":"A child with Kabuki syndrome and primary sclerosing cholangitis successfully treated with ursodiol and cholestryamine","volume":"43","author":"Suskind DL","year":"2006","unstructured":"Suskind DL, Finn L, Wahbeh G, Christie D, Horslen S. A child with Kabuki syndrome and primary sclerosing cholangitis successfully treated with ursodiol and cholestryamine. J Pediatr Gastroenterol Nutr. 2006, 43:542-4. 10.1097\/01.mpg.0000228114.06488.ef","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli ML","year":"2020","unstructured":"Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020, 38:621-48. 10.1146\/annurev-immunol-100919-023531","journal-title":"Annu Rev Immunol"},{"key":"ref15","unstructured":"Lexi-Drugs. (2022). Accessed. November 6, 2022: http:\/\/online.lexi.com.."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26 Suppl 3","author":"Archier E","year":"2012","unstructured":"Archier E, Devaux S, Castela E, et al.. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012, 26 Suppl 3:22-31. 10.1111\/j.1468-3083.2012.04520.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","article-title":"Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications","volume":"27","author":"Shalabi MMK","year":"2022","unstructured":"Shalabi MMK, Garcia B, Coleman K, Siller A, Jr., Miller AC, Tyring SK. Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications. Skin Therapy Lett. 2022, 27:4-9.","journal-title":"Skin Therapy Lett"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp K","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, et al.. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021, 85:863-72. 10.1016\/j.jaad.2021.04.085","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi F","year":"2021","unstructured":"Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021, 12:790125. 10.3389\/fimmu.2021.790125","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin D","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, et al.. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020, 396:110-20. 10.1016\/S0140-6736(20)30609-7","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/133707-vitiligo-in-a-patient-with-kabuki-syndrome-case-study-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:10Z","timestamp":1707508630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/133707-vitiligo-in-a-patient-with-kabuki-syndrome-case-study-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.34143","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,24]]}}}